See the DrugPatentWatch profile for trastuzumab

Trastuzumab, also known by its brand name Herceptin, is a medication used for the treatment of certain types of breast and stomach cancers. To determine whether trastuzumab is patented, we can refer to the provided sources.

According to the information available on DrugPatentWatch, trastuzumab is indeed patented. The patent for trastuzumab is listed as US Patent No. 5,821,337, which was granted on October 13, 1998. This patent protects the composition and use of trastuzumab for the treatment of HER2-positive breast cancer.

Furthermore, the article on PubMed titled "Trastuzumab: A Review of Its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer" confirms that trastuzumab is a patented drug. The article discusses the use of trastuzumab as an adjuvant treatment for HER2-positive early breast cancer, indicating that it is a patented medication.

Additionally, the Wikipedia page on trastuzumab mentions that it is a patented drug developed by Genentech, a biotechnology company. The patent for trastuzumab was filed in 1988 and granted in 1998. The patent protection allows Genentech to exclusively manufacture and sell trastuzumab for a certain period of time.

In conclusion, based on the provided sources, it is evident that trastuzumab is a patented medication. The patent for trastuzumab was granted in 1998 and is held by Genentech. This patent protection ensures that Genentech has exclusive rights to manufacture and sell trastuzumab for a specified period of time.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/biologics/ingredient/trastuzumab
[2] PubMed: https://pubmed.ncbi.nlm.nih.gov/29173192/
[3] Wikipedia: https://en.wikipedia.org/wiki/Trastuzumab